The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially .beta.-aminoisobutyric acid, in various bodily fluid s, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liqu id chromatography system, for use in the invention are disclosed.
DIAGNOSTIC METHODS FOR DETERMINING SUSCEPTIBILITY TO CONVULSIVE CONDITIONS